This favorable toxicity profile can be explained by a kinetic binding model of anti-EGFR antibodies, where intermediate affinity of nimotuzumab (KD = 10−9M) to the receptor, results in a high tumor uptake and low uptake into normal tissues [20, 21]. Here, EGFR is linked to neoplasm.